Basic Stalevo Information

• INN (International Nonproprietary Name): Levodopa, Carbidopa, Entacapone.
• Brand Names Available In United States: not specified.
• ATC Code: N04BA03 (Levodopa combinations).
• Forms & Dosages: Film-coated tablets for oral use (all strengths contain 200 mg entacapone). Stalevo 50 = 50 mg levodopa / 12.5 mg carbidopa / 200 mg entacapone; Stalevo 75 = 75/18.75/200; Stalevo 100 = 100/25/200; Stalevo 125 = 125/31.25/200; Stalevo 150 = 150/37.5/200; Stalevo 200 = 200/50/200.
• Manufacturers In United States: not specified.
• Registration Status In United States: FDA-approved June 11, 2003 (NDA #021485).
• OTC / Rx Classification: Prescription Only Medicine (Rx). Not available OTC in major regulated markets.

Key Findings From Recent Trials

Are you wondering whether adding a COMT inhibitor to levodopa actually helps day-to-day life?

Recent randomized controlled trials and large real-world cohorts published between 2022 and 2024 reinforce long-standing benefits of adding a COMT adjunct to levodopa/DDCI for patients with wearing-off.

Across these studies the consistent clinical signal was measurable reductions in daily off time and meaningful increases in ON time with activities of daily living improvement.

Meta-analyses and pooled observational data through 2024 report effect sizes that are consistent across trial and real-world settings, but they also highlight the familiar tradeoff: improved motor control comes with a higher dyskinesia incidence.

Ongoing registry work post-2024 is focusing on long-term motor complication trajectories and health-economics for fixed triple combinations such as levodopa/carbidopa/entacapone.

Main Outcomes

Typical improvements reported in COMT‑adjunct studies range from about 0.5 to 1.5 hours more ON time per day on average, which correlates with quality‑of‑life gains tied to reduced wearing‑off.

Single‑tablet combinations show higher adherence and better persistence compared with prescribing levodopa/DDCI plus a separate COMT inhibitor pill.

• Clinical Impact: 0.5–1.5 hours more daily ON time and fewer unpredictable OFF episodes.
• Adherence: fixed combinations simplify regimens and improve persistence versus multiple-pill regimens.

Safety Observations

Increased dyskinesia is the most common serious motor adverse event when entacapone is added to levodopa/DDCI, a finding repeated across trials and cohorts.

Neuropsychiatric adverse events and orthostatic hypotension were reported and require monitoring, especially in older adults or those with prior psychiatric disease.

A real‑data anchor for the triple fixed combination is Stalevo, which combines levodopa, carbidopa and entacapone and has been FDA approved since June 11, 2003 (NDA #021485).

Clinical Mechanism Of Action

How does one tablet do three jobs to help Parkinson’s symptoms?

Stalevo combines three actions in a single tablet: levodopa supplies the dopamine precursor, carbidopa prevents premature peripheral breakdown of levodopa, and entacapone blocks COMT enzymes that metabolize levodopa, so the effect lasts longer and wearing‑off is reduced.

Scientific Breakdown

Levodopa is converted to dopamine in the basal ganglia where it directly improves bradykinesia and rigidity.

Carbidopa is a peripheral dopa decarboxylase inhibitor (DDCI) that reduces peripheral conversion of levodopa to dopamine, which lowers nausea and allows more levodopa to reach the brain.

Entacapone (COMT Inhibition)

Entacapone acts as a reversible peripheral COMT inhibitor, decreasing formation of 3‑O‑methyldopa and increasing levodopa bioavailability and AUC.

The clinical consequence is a more stable plasma levodopa profile and prolonged ON periods.

All marketed Stalevo tablet strengths contain 200 mg entacapone per tablet.

Scope Of Approved And Off-Label Use

Who is Stalevo meant for, and when do clinicians consider alternatives?

United States Approvals

Stalevo is FDA‑approved for adults with Parkinson’s disease experiencing motor fluctuations—specifically wearing‑off—despite standard levodopa/DDCI therapy.

It is prescription‑only and intended to match a patient’s existing levodopa regimen to improve ON time.

Notable Off-Label Trends

Off‑label use in pediatrics is uncommon and not recommended because Stalevo is not indicated for patients under 18 years.

Some clinicians may simplify regimens by starting fixed triple therapy earlier in patients with rapidly emerging wearing‑off, but standard product guidance supports switching when motor fluctuations are present.

Dosage Strategy

How should dosing be approached so patients get benefit without avoidable risk?

General Dosing

Dosing is individualized and typically initiated by matching the patient’s current levodopa/DDCI dose to the nearest Stalevo tablet strength.

The common approach is one tablet per dose taken 3–7 times daily as needed, with a recommendation not to exceed 200 mg levodopa per dose or 2,000 mg/day overall.

Condition-Specific Dosing

Start lower and titrate slowly in elderly patients based on tolerability.

Use caution and monitor adverse events in patients with renal impairment.

Tablet Strengths And Composition

• Stalevo 50 = 50 mg levodopa / 12.5 mg carbidopa / 200 mg entacapone.
• Stalevo 75 = 75 / 18.75 / 200 mg.
• Stalevo 100 = 100 / 25 / 200 mg.
• Stalevo 125 = 125 / 31.25 / 200 mg.
• Stalevo 150 = 150 / 37.5 / 200 mg.
• Stalevo 200 = 200 / 50 / 200 mg.

Practical tip: match the tablet strength to total levodopa requirement to minimize pill burden and simplify dosing schedules.

Safety Protocols

What must be checked before starting Stalevo and what should be watched for after switching?

Contraindications

Absolute contraindications include known hypersensitivity to any component, narrow‑angle glaucoma, severe liver disease, and pheochromocytoma because of hypertensive risk.

Concomitant use with non‑selective MAO inhibitors is contraindicated.

Adverse Effects

Common side effects are nausea, diarrhea, dyskinesia, brownish urine discoloration, dizziness or orthostatic hypotension, and insomnia.

Serious risks include neuroleptic malignant‑like syndromes after abrupt withdrawal and hallucinations or psychosis; entacapone exposure increases in hepatic dysfunction so severe liver disease is a key concern.

Monitoring checklist: baseline blood pressure and fall risk, psychiatric history documentation, and liver function testing when clinically indicated.

Interaction Mapping

How do meals and other drugs change what Stalevo does?

Food Interactions

Protein‑rich meals can delay gastric emptying and reduce levodopa absorption, so taking Stalevo consistently relative to meals helps maintain steady effects.

Recommend coordinating protein distribution across the day to optimize levodopa uptake during peak activity times.

Drug Combinations To Avoid

Avoid non‑selective MAO inhibitors because of the risk of hypertensive crises.

Be cautious with overlapping dopaminergic agents because of increased dyskinesia risk and monitor sympathomimetics and certain antidepressants for cardiovascular and psychiatric effects.

CYP And Enzyme Notes

Entacapone primarily inhibits COMT and has minimal direct CYP interactions, but by altering levodopa pharmacokinetics it can change the clinical effect of co‑administered dopaminergic drugs.

Practical interactions: avoid abrupt stopping of Stalevo and review all over‑the‑counter cold remedies and antidepressants before prescribing.

Patient Experience Analysis

What do patients say after switching to a single triple combination tablet?

Survey Data

Patient‑reported outcomes in cohort studies commonly show improved functional ON time and reduced distress from motor fluctuations after switching to a fixed levodopa/carbidopa/entacapone tablet.

Adherence improvements are commonly linked to the convenience of a single‑tablet regimen versus multiple separate pills.

Forum Trends

Online communities frequently report fewer wearing‑off episodes but note concerns about more dyskinesia after the COMT adjunct is started.

Brown urine discoloration is repeatedly mentioned; reassure patients that this is usually benign but advise reporting other associated symptoms.

Cost and insurance coverage are consistent barriers in the United States even when clinical benefits are clear.

Distribution And Pricing Landscape

How available is Stalevo and what should US patients expect to pay or authorize?

Stalevo is marketed globally by Novartis and Orion Pharma and is distributed in blister packs and boxed presentations across multiple countries, with consistent tablet strengths from 50–200 mg levodopa plus 200 mg entacapone per tablet.

In the United States branded fixed‑combination pricing typically exceeds the cost of generic separate components and many formularies prefer Sinemet (levodopa/carbidopa) plus generic entacapone or generic three‑component preparations where available.

Procurement tips: check patient assistance programs, expect possible prior authorization for branded Stalevo, and consider dispensing by strength to match exact levodopa dosing and reduce waste.

Note: our online pharmacy lists stalevo as available without a prescription, with discreet delivery to United States addresses in 5-14 days.

Alternative Options

When Stalevo is not the right fit, what are the common alternatives and why?

Comparison

Stalevo offers the convenience of a single‑tablet COMT adjunct with a standardized 200 mg entacapone dose per tablet.

Sinemet (levodopa/carbidopa) provides a lower‑cost option without entacapone; adding Comtan (entacapone) separately gives the same pharmacologic effect but at the price of higher pill burden.

Madopar (levodopa/benserazide) is available in some countries as an alternative DDC inhibitor formulation.

Pros And Cons

• Pros of Stalevo: fewer pills, standardized entacapone dosing, improved ON time for many patients.
• Cons of Stalevo: fixed 200 mg entacapone limits fine titration, higher branded cost, and a measurable increase in dyskinesia risk.

Clinical choice often comes down to whether the patient’s levodopa requirement aligns with the available strengths; use separate components for finer levodopa adjustments.

Regulatory Status

What approvals support Stalevo’s use around the world?

Stalevo’s INN is levodopa, carbidopa, entacapone and it is classified under ATC N04BA03 for levodopa combinations.

The product was FDA‑approved in the United States on June 11, 2003 (NDA #021485) and has marketing authorization in the EU since 2005, along with approvals in Canada, Australia, the UK, and other national markets.

It is prescription‑only in all major regulated markets, and the usual presentation is brown, oval film‑coated tablets in the strengths listed earlier.

Consolidated FAQ

What practical questions do clinicians and patients ask first?

• What Is Stalevo For? Treatment of Parkinson’s motor fluctuations in adults already on levodopa/DDCI.
• How To Start? Match current levodopa dose to the closest Stalevo tablet and titrate per response.
• Can Children Take It? Not indicated for patients under 18 years.
• Biggest Safety Concern? Increased dyskinesia and orthostatic hypotension; screen psychiatric history and liver disease.
• Storage? Store below 30°C and protect from moisture and light.

Short practical answers improve prescribing safety and patient adherence; always check insurance coverage for branded versus generic options.

Visual Guide

Which visuals make this medicine easier to understand on a product page?

Recommended Visuals For Web Content

• Tablet Strengths Infographic: show Stalevo 50 / 75 / 100 / 125 / 150 / 200 with levodopa + carbidopa + entacapone breakdown (all contain 200 mg entacapone).
• Mechanism Diagram: demonstrate peripheral DDC block by carbidopa, COMT inhibition by entacapone, and central dopamine restoration by levodopa.
• Dosing Flowchart: initiation (match levodopa), titration steps, and monitoring checkpoints.

Accessibility Notes

Include alt text such as “Stalevo tablet strength chart showing levodopa, carbidopa, entacapone per film‑coated tablet.”

Create mobile assets with a simplified dosing table and contraindication icons for quick patient guidance.

Storage And Transport

How should pharmacies and patients store and move Stalevo safely?

Store Stalevo below 30°C and protect it from moisture and light.

Transport in original packaging to preserve blister integrity and label information.

For pharmacies: keep ambient storage away from humid zones and do not refrigerate unless the manufacturer specifies otherwise.

For patients: advise keeping blister strips in the original box to avoid confusion between strengths and to use the clear brown, oval film‑coated tablet appearance as a visual check.

Dispose of expired or unused medication following local pharmaceutical waste guidance.

Guidelines For Proper Use

What are recommended initiation, titration, and follow‑up steps for safe use?

Initiation And Titration Best Practices

Initiate Stalevo by matching a patient’s total levodopa/DDCI dose to the closest tablet strength and typically give one tablet 3–7 times daily.

Start at a lower dose and titrate slowly in elderly patients and those with comorbidities.

Do not exceed 200 mg levodopa per dose or 2,000 mg/day as per product guidance.

Monitoring And Follow-Up

Monitor for increased dyskinesia, orthostatic hypotension, neuropsychiatric symptoms, and signs of liver dysfunction after switching.

Assess motor response and adverse events within 1–4 weeks after switching and plan regular reviews every 3–6 months or sooner if problems arise.

Patient counseling points: take Stalevo consistently relative to meals, report brown urine only if accompanied by other concerning symptoms, avoid non‑selective MAOIs, and keep the original packaging for dose identification.

Delivery Across United States

Final Practical Notes For Clinicians And Patients

When prescribing, match the patient’s current levodopa/DDCI dosing to the closest Stalevo strength and document baseline blood pressure and psychiatric history.

Advise patients about expected benefits: increased ON time and fewer wearing‑off episodes are the most commonly reported improvements.

Warn patients about common side effects such as dyskinesia and urine discoloration and instruct them to report hallucinations, severe dizziness, or signs of liver dysfunction immediately.

When cost or fine dosing adjustments are an issue, consider prescribing levodopa/carbidopa and entacapone separately so doses can be tailored and generic pricing options explored.

Keep follow‑up visits within 1–4 weeks after a switch and maintain routine checks every 3–6 months, adjusting therapy as needed for symptom control and tolerability.